ALIMERA SCIENCES, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-01: Form 8-K; Period of report 2021-11-30; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; Details 5.02.
- 2021-10-28: Form 8-K; Period of report 2021-10-28; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2021-08-13: Form 8-K; Period of report 2021-08-13; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2021-06-16: Form 8-K; Period of report 2021-06-15; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-01 | 8-K | 2021-11-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 (d) On December 1, 2021, Alimera Sciences, Inc. (the “Company”) issued a press release announcing that, based upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”), on November 30, 2021 the Board appointed Erin Parsons to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders in 2022. 7.01 On December 1, 2021, the Company issued a press release announcing the appointment of Ms. Parsons to the Board. | alim-20211130x8k.htm |
| 2021-10-28 | 8-K | 2021-10-28 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On October 28, 2021, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the three and nine months ended September 30, 2021 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20211028x8k.htm |
| 2021-08-13 | 8-K | 2021-08-13 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On August 13, 2021, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the three and six months ended June 30, 2021 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20210813x8k.htm |
| 2021-06-16 | 8-K | 2021-06-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 (e) On June 15, 2021, Alimera Sciences, Inc. (the “Company”) held its 2021 annual meeting of stockholders (the “Annual Meeting”). 5.07 Proposal 1: The election of two directors to serve as Class II directors for a term of three years until the 2024 annual meeting of stockholders. | alim-20210615x8k.htm |
| 2021-04-28 | 8-K | 2021-04-28 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On April 28, 2021, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the first quarter ended March 31, 2021 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20210428x8k.htm |
| 2021-04-14 | 8-K | 2021-04-12 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information regarding the issuance of the Shares included under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 5.02 On April 12, 2021, Mary Szela notified the Company that she would not stand for re-election to the Board at the 2021 annual meeting of stockholders (but intended to continue to serve as a director through the annual meeting). | alim-20210414x8k.htm |
| 2021-03-30 | 8-K | 2021-03-30 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Definitive Material Agreement. 2.03 The information disclosed in Item 1.01 above is incorporated herein by reference. | alim-20210330x8k.htm |
| 2021-02-24 | 8-K | 2021-02-24 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On February 24, 2021, Alimera Sciences, Inc. (“Alimera”) issued a press release regarding its results of operations and financial condition for the fourth quarter and full year ended December 31, 2020 as well as a corporate update. 7.01 The conference call and webcast, and the press release, include or will include a non-GAAP financial measure, Adjusted EBITDA. | alim-20210224x8k.htm |
| 2021-02-19 | 8-K | 2021-02-11 | 7.01 Regulation FD Disclosure | 7.01 Alimera Sciences, Inc. (the Company) is filing this Current Report on Form 8-K to report that effective February 11, 2021, its Chief Medical Officer, Dr. Samer Kaba, is no longer employed by the Company. | alim-20210211x8k.htm |
| 2021-01-19 | 8-K | 2021-01-19 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 19, 2021, Alimera Sciences, Inc. (“Alimera” or “we”) issued a press release regarding its expectations for its consolidated net revenue for the fourth quarter and full-year 2020. 7.01 In addition, Richard S. Eiswirth, Jr., Alimera’s President and Chief Executive Officer, stated in the press release: “While COVID-19 presented new obstacles, we proved our ability to adapt and maintain our business in a challenging year. | alim-20210119x8k.htm |
| 2021-01-08 | 8-K | 2021-01-08 | 7.01 Regulation FD Disclosure | 7.01 Alimera Sciences, Inc. (the Company) is filing this Current Report on Form 8-K to report that all shares of the Company’s Series C Convertible Preferred Stock, par value $0.01 per share (Series C Preferred Stock), have been converted into shares of the Company’s common stock, par value $0.01 per share (Common Stock). | alim-20210108x8k.htm |